User:Mr. Ibrahem/MVA-BN smallpox vaccine

MVA-BN smallpox vaccine is a smallpox vaccine used to prevent smallpox, monkeypox, and vaccinia. It is recommended in people at high risk of these disease, including after exposure. It was previously estimated to be more than 85% effective against monkeypox. It is given by injection under the skin as two doses 4-weeks apart.

Side effects are generally mild. Commonly these include pain at the site of injection, muscle pain, headache, tiredness, and nausea. Other side effects may include anaphylaxis. For people with eczema or a weakened immune system, MVA-BN is safer then ACAM2000. There is no evidence of harm in pregnancy, though such use has not been well studied. It is a live vaccine, using the vaccinia virus, but a version that cannot duplicate itself.

MVA-BN was approved for medical use in Canada and Europe in 2013, and the United States in 2019. It is sold under the brands Jynneos, Imvamune, and Imvanex. As of 2022 there are about 16 million doses available globally, with the United States to get 14 million. In the 2000s it cost government about 29 USD a dose. Bavarian Nordic owns the patent; though received 2 billion USD from the United States government to support its development.